Significant progress has been made with the discovery of ESR1 mutations, which are detectable in less than 1% of primary BC, but are enriched in metastatic luminal BC during adjuvant ET (in up to 15%–30%) and lead to ligand-independent autocrine tumor cell growth. The gene discussed is ESR1; the disease is breast cancer.